Bio-Techne (TECH)

• Market cap: $7.92B
• 1 day: -1.96%
• 5 days: 1.92%
• 1 month: -2.11%
• 3 months: -15.63%
• 6 months: -33.25%
• Year to date: -29.32%
• 1 year: -34.29%
• 5 years: -20.55%
• 10 years: 106.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Employees: 3,100

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

547% more call options, than puts

Call options by funds: $5.54M | Put options by funds: $856K

18% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 66

2.82% more ownership

Funds ownership: 98.6% [Q4 2024] → 101.42% (+2.82%) [Q1 2025]

0% more funds holding

Funds holding: 564 [Q4 2024] → 566 (+2) [Q1 2025]

1% less repeat investments, than reductions

Existing positions increased: 201 | Existing positions reduced: 204

17% less funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 5 (-1) [Q1 2025]

17% less capital invested

Capital invested by funds: $11.3B [Q4 2024] → $9.39B (-$1.89B) [Q1 2025]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $59 17% upside
• Avg. target: $67 33% upside
• High target: $75 48% upside

6 analyst ratings

• positive: 4 67%
• neutral: 2 33%
• negative: 0 0%

Benchmark Robert Wasserman	48% upside $75	Buy Reiterated	5 Jun 2025
Wells Fargo Brandon Couillard	17% upside $59	Overweight Initiated	30 May 2025
UBS Dan Leonard	39% upside $70	Buy Maintained	9 May 2025
RBC Capital Conor McNamara	25% upside $63	Sector Perform Maintained	8 May 2025
Stifel Daniel Arias	19% upside $60	Hold Maintained	8 May 2025